DE69813025T2 - Verwendung eines aromataseinhibitors zur behandlung von niedrigem androgen/estrogen verhältnis und zur behandlung der detrusor-blasenschliessmuskelsdyssynergie, und untersuchungsmethoden der dyssynergie in männlichen nagetieren - Google Patents
Verwendung eines aromataseinhibitors zur behandlung von niedrigem androgen/estrogen verhältnis und zur behandlung der detrusor-blasenschliessmuskelsdyssynergie, und untersuchungsmethoden der dyssynergie in männlichen nagetieren Download PDFInfo
- Publication number
- DE69813025T2 DE69813025T2 DE69813025T DE69813025T DE69813025T2 DE 69813025 T2 DE69813025 T2 DE 69813025T2 DE 69813025 T DE69813025 T DE 69813025T DE 69813025 T DE69813025 T DE 69813025T DE 69813025 T2 DE69813025 T2 DE 69813025T2
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- detrusor
- dysynergy
- bladdermuscle
- treating low
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- 239000003098 androgen Substances 0.000 title abstract 2
- 239000000262 estrogen Substances 0.000 title abstract 2
- 229940011871 estrogen Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000000796 flavoring agent Substances 0.000 title 1
- 235000019634 flavors Nutrition 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 210000005070 sphincter Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Accommodation For Nursing Or Treatment Tables (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/989,447 US5972921A (en) | 1997-12-12 | 1997-12-12 | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
PCT/FI1998/000954 WO1999030708A2 (en) | 1997-12-12 | 1998-12-09 | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69813025D1 DE69813025D1 (de) | 2003-05-08 |
DE69813025T2 true DE69813025T2 (de) | 2004-01-15 |
Family
ID=25535123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69813025T Expired - Lifetime DE69813025T2 (de) | 1997-12-12 | 1998-12-09 | Verwendung eines aromataseinhibitors zur behandlung von niedrigem androgen/estrogen verhältnis und zur behandlung der detrusor-blasenschliessmuskelsdyssynergie, und untersuchungsmethoden der dyssynergie in männlichen nagetieren |
Country Status (17)
Country | Link |
---|---|
US (2) | US5972921A (de) |
EP (1) | EP1043993B1 (de) |
JP (1) | JP2002508322A (de) |
KR (1) | KR20010032909A (de) |
CN (1) | CN1281361A (de) |
AT (1) | ATE235904T1 (de) |
AU (1) | AU743196B2 (de) |
BR (1) | BR9813534A (de) |
CA (1) | CA2312347A1 (de) |
DE (1) | DE69813025T2 (de) |
EE (1) | EE200000346A (de) |
ES (1) | ES2191358T3 (de) |
HU (1) | HUP0100762A3 (de) |
NO (1) | NO20002960L (de) |
NZ (1) | NZ504632A (de) |
PL (1) | PL341653A1 (de) |
WO (1) | WO1999030708A2 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972921A (en) | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
DE50016101D1 (de) * | 1999-08-13 | 2011-06-09 | Curadis Gmbh | Substanzen und mittel zur positiven beeinflussung von kollagen |
WO2001076574A2 (en) * | 2000-04-12 | 2001-10-18 | Novartis Ag | Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
US20030083342A1 (en) * | 2002-08-27 | 2003-05-01 | Steele Ronald Edward | Combination of organic compounds |
US6495534B2 (en) * | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
FI20010905A0 (fi) * | 2001-05-02 | 2001-05-02 | Vetcare Oy | Uusi eläinlääke |
US6607755B2 (en) | 2001-06-21 | 2003-08-19 | Michael Donald Farley | Anti-aromatase pharmaceutical composition for controlling testosterone/estrone ratios |
US6931276B2 (en) * | 2002-04-29 | 2005-08-16 | Tomi Streng | Method and device for use in micturition studies |
US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
EP1656129A4 (de) * | 2003-08-22 | 2009-03-11 | Univ Virginia | Blockade von mtor zur prävention einer hormonalen adaptiven antwort |
MX2008014825A (es) * | 2006-05-22 | 2008-12-01 | Hormos Medical Ltd | Moduladores selectivos del receptor de estrogeno o inhibidores de aromatasa para tratar prostatitis cronica no bacteriana. |
PT2753312T (pt) * | 2011-09-08 | 2017-02-03 | Mereo Biopharma 2 Ltd | Utilização de um inibidor da aromatase para o tratamento de hipogonadismo e doenças relacionadas |
CN102641502A (zh) * | 2012-04-25 | 2012-08-22 | 中国农业大学 | 芳香酶抑制剂的新用途 |
EP3120859B1 (de) * | 2014-03-21 | 2023-05-24 | Dong Wha Pharm. Co., Ltd. | Zusammensetzung zur vorbeugung, behandlung und linderung von harnwegsstörungen mit extrakt von piper longum l. |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2273704B (en) * | 1992-12-16 | 1997-01-22 | Orion Yhtymae Oy | Triazolyl diaryl selective aromatase inhibiting compounds |
DE4435368A1 (de) | 1994-09-22 | 1996-03-28 | Schering Ag | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
US5972921A (en) | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
-
1997
- 1997-12-12 US US08/989,447 patent/US5972921A/en not_active Expired - Fee Related
-
1998
- 1998-09-12 US US09/581,128 patent/US6316431B1/en not_active Expired - Lifetime
- 1998-12-09 EP EP98958935A patent/EP1043993B1/de not_active Expired - Lifetime
- 1998-12-09 BR BR9813534-1A patent/BR9813534A/pt not_active IP Right Cessation
- 1998-12-09 JP JP2000538691A patent/JP2002508322A/ja active Pending
- 1998-12-09 KR KR1020007006244A patent/KR20010032909A/ko not_active Application Discontinuation
- 1998-12-09 ES ES98958935T patent/ES2191358T3/es not_active Expired - Lifetime
- 1998-12-09 AU AU14897/99A patent/AU743196B2/en not_active Ceased
- 1998-12-09 NZ NZ504632A patent/NZ504632A/en unknown
- 1998-12-09 AT AT98958935T patent/ATE235904T1/de not_active IP Right Cessation
- 1998-12-09 HU HU0100762A patent/HUP0100762A3/hu unknown
- 1998-12-09 CA CA002312347A patent/CA2312347A1/en not_active Abandoned
- 1998-12-09 EE EEP200000346A patent/EE200000346A/xx unknown
- 1998-12-09 WO PCT/FI1998/000954 patent/WO1999030708A2/en not_active Application Discontinuation
- 1998-12-09 PL PL98341653A patent/PL341653A1/xx unknown
- 1998-12-09 DE DE69813025T patent/DE69813025T2/de not_active Expired - Lifetime
- 1998-12-09 CN CN98812074A patent/CN1281361A/zh active Pending
-
2000
- 2000-06-09 NO NO20002960A patent/NO20002960L/no unknown
Also Published As
Publication number | Publication date |
---|---|
WO1999030708A2 (en) | 1999-06-24 |
DE69813025D1 (de) | 2003-05-08 |
NO20002960D0 (no) | 2000-06-09 |
EP1043993A2 (de) | 2000-10-18 |
WO1999030708A3 (en) | 1999-08-19 |
BR9813534A (pt) | 2000-11-14 |
NZ504632A (en) | 2001-10-26 |
CA2312347A1 (en) | 1999-06-24 |
AU743196B2 (en) | 2002-01-24 |
ES2191358T3 (es) | 2003-09-01 |
JP2002508322A (ja) | 2002-03-19 |
PL341653A1 (en) | 2001-04-23 |
EP1043993B1 (de) | 2003-04-02 |
HUP0100762A3 (en) | 2002-12-28 |
CN1281361A (zh) | 2001-01-24 |
NO20002960L (no) | 2000-08-14 |
ATE235904T1 (de) | 2003-04-15 |
EE200000346A (et) | 2001-10-15 |
AU1489799A (en) | 1999-07-05 |
HUP0100762A2 (hu) | 2001-08-28 |
US6316431B1 (en) | 2001-11-13 |
KR20010032909A (ko) | 2001-04-25 |
US5972921A (en) | 1999-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69813025T2 (de) | Verwendung eines aromataseinhibitors zur behandlung von niedrigem androgen/estrogen verhältnis und zur behandlung der detrusor-blasenschliessmuskelsdyssynergie, und untersuchungsmethoden der dyssynergie in männlichen nagetieren | |
DE69827001D1 (de) | Gewebedezellularization | |
DE69611251D1 (de) | Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges | |
ATE208210T1 (de) | Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs | |
DE69818278D1 (de) | Steroid sulfataseinhibitoren, verfahren zu ihrer herstellung und verwendung | |
ATE192924T1 (de) | Liposomal verkapseltes taxol, seine herstellung und seine verwendung | |
ATE369871T1 (de) | Verfahren zur behandlung von hautkrebs mittels zusammensetzungen, die einen endothelinrezeptor-b-hemmer enthalten | |
ATE342278T1 (de) | Verfahren zur behandlung von diabetes mittels kgf | |
TR200201246T2 (tr) | Hidroksieikosatetraenoik asit türevlerini ihtiva eden bileşimler ve göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri | |
ATE311853T1 (de) | Verwendung von krillenzymen zur behandlung von zahnbelag | |
DE69912815D1 (de) | Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien | |
DE69921130D1 (de) | Verfahren und stoffe zur behandlung des prostatakarzinomes | |
NO20053626L (no) | Blanding omfattende en kombinasjon av en aromataseinhibitor, et progestin og et ostrogen for anvendelse av behandling av endomeriose | |
AU2002220803A1 (en) | Composition, in particular cosmetic, containing 7-hydroxy dhea and/or 7-keto dhea and at least an isoflavonoid | |
DE59710660D1 (de) | Kombination von dehydroepiandrosteron und aromatasehemmern und verwendung dieser kombination zur herstellung eines arzneimittels zur behandlung eines relativen und absoluten androgenmangels beim mann | |
DE60113975D1 (de) | Verwendung von fulvestrant in der behandlung von resistentem brustkrebs | |
DE60137721D1 (de) | Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs | |
ATE200414T1 (de) | Verwendung eines mittels zur haarbehandlung | |
ATE401094T1 (de) | Verwendung eines ginkgo extraktes zur behandlung von krebs welcher durch überexpression von peripherem benzodiazepin rezeptor protein gekennzeichnet ist | |
ATE419037T1 (de) | Verwendung eines mittel zur therapie der herzhypertrophie | |
DE59907558D1 (de) | Mittel zur stabilisierung von lebensmitteln und kosmetischen mitteln sowie verfahren zu dessen herstellung | |
CA2421302A1 (en) | 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds | |
DE59913720D1 (de) | Verfahren zur Herstellung eines Extraktes aus Copalchirinde und Verwendung der Neoflavonoide zur Behandlung von Diabetes | |
MD1365F1 (en) | Method of prognostication of bone metastasis appearing at patients affected with mammary gland cancer | |
ATE222265T1 (de) | Verfahren zur behandlung von dicotylensamen um eine endospermfraktion zu erhalten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |